NovaBridge Biosciences (NBP)
NBPNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$0.8999
-0.0089 (-0.98%) today
Regular session, Nov 10, 10:00 AM ET
- Market cap
- $103.83m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- $0.8600 to $0.9100
- 52-week range
- $0.8800 to $5.19
- Average volume
- 510.2k
- Previous close
- $0.9088
Analysts
1 coveringBuy1 buy, 0 hold, 0 sell
Targets a year out average $9.00, +900.1% from here
Earnings
next estimate $-0.0800Next report
Financials
| Quarter | Sep 2019 | Dec 2019 |
|---|---|---|
| Revenue | $2.02m | $104.0k |
| Gross profit | $2.02m | $104.0k |
| Operating income | -$38.38m | -$51.86m |
| Net income | -$29.75m | -$53.87m |
News
8 latest- Novabridge Biosciences Picks Givastomig Dose After Promising Gastric Cancer Data, Aligns With FDAMarketBeat · Nov 3, 2026
- I-Mab Appoints Charles Silberstein as Chief Financial Officer Effective November 2, 2026Fintel · Oct 28, 2026
- NovaBridge Names Chuck Silberstein CFO To Succeed Kyler Lei, Shares Jump In Pre-market RTTNews · Oct 28, 2026
- I-Mab Reports Mature Phase 1b Data at ESMO 2026Fintel · Oct 26, 2026
- Weekly Buzz: AZN, ALVO Score FDA Nod; EYPT Cuts Jobs; RHHBY, GEHC Enter Deal; VERA Posts Trial Win RTTNews · Oct 23, 2026
- NovaBridge Biosciences Reports Ragistomig Phase 1 Clinical Data Presentation at ESMO Congress 2026Fintel · Oct 23, 2026
- NovaBridge Acquires YOL104-2 From YOLO Via Visara; To Continue Drug Development For OSSN RTTNews · Oct 21, 2026
- NovaBridge Reports Wider H1 Loss; Advances Givastomig And VIS-101 Programs RTTNews · Aug 20, 2026
The company
NovaBridge Biosciences ('NovaBridge') (NASDAQ: NBP) is a global biotechnology company focused on identifying, developing and maximizing the value of differentiated therapeutic assets. The Company advances programs through clinical development and pursues the financing and partnering strategies best suited to each opportunity. NovaBridge's portfolio is led by givastomig, a Claudin 18.2 * 4-1BB bispecific antibody being developed for the potential treatment of gastrointestinal malignancies, and Visara, its majority-owned ophthalmology subsidiary. Through Visara, NovaBridge is building a diversified ophthalmology franchise designed to address unmet needs across diseases of the front and back of the eye. NovaBridge's objective is to build a sustainable biotechnology company by repeatedly identifying differentiated innovation, advancing it efficiently, and bringing novel therapies to patients through the path best suited to each opportunity.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- Asia
- Website
- novabridge.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.